Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Sandrock

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Annals of Neurology|October 23, 2021
Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and GreiciusAlfred Sandrock
Expert Review of Neurotherapeutics|April 28, 2005
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MSRichard A Rudick, Alfred Sandrock
Annals of Neurology|March 13, 2010
Reply: To PMID 19798640Carmen Bozic, Julia LaGuette, Alfred Sandrock
The New England Journal of Medicine|June 11, 2005
Natalizumab and progressive multifocal leukoencephalopathyBurt Adelman, Alfred Sandrock, Michael A Panzara
The International Journal of Biochemistry & Cell Biology|May 13, 2008
LINGO-1 and its role in CNS repairSha Mi, Alfred Sandrock, Robert H Miller
Journal of Neuroimmunology|August 12, 2004
The blood-brain barrier as target of multiple sclerosis research and therapy. Report of an international scientific meeting, Würzburg, January 23/24, 2004Ralf Gold, Richard M Ransohoff, Alfred Sandrock, et al.
Annals of Neurology|December 14, 2011
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1Carmen Bozic, Sandra Richman, Tatiana Plavina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 22, 2022
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosisIh Chang, Ludwig Kappos, Gavin Giovannoni, et al.
The New England Journal of Medicine|May 18, 2012
Risk of natalizumab-associated progressive multifocal leukoencephalopathyGary Bloomgren, Sandra Richman, Christophe Hotermans, et al.
Acta Neuropathologica|May 17, 2022
Alzheimer disease neuropathology in a patient previously treated with aducanumabEdward D Plowey, Thierry Bussiere, Raj Rajagovindan, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Annals of Neurology|October 23, 2021
Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and GreiciusAlfred Sandrock
Expert Review of Neurotherapeutics|April 28, 2005
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MSRichard A Rudick, Alfred Sandrock
Annals of Neurology|March 13, 2010
Reply: To PMID 19798640Carmen Bozic, Julia LaGuette, Alfred Sandrock
The New England Journal of Medicine|June 11, 2005
Natalizumab and progressive multifocal leukoencephalopathyBurt Adelman, Alfred Sandrock, Michael A Panzara
The International Journal of Biochemistry & Cell Biology|May 13, 2008
LINGO-1 and its role in CNS repairSha Mi, Alfred Sandrock, Robert H Miller
Journal of Neuroimmunology|August 12, 2004
The blood-brain barrier as target of multiple sclerosis research and therapy. Report of an international scientific meeting, Würzburg, January 23/24, 2004Ralf Gold, Richard M Ransohoff, Alfred Sandrock, et al.
Annals of Neurology|December 14, 2011
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1Carmen Bozic, Sandra Richman, Tatiana Plavina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 22, 2022
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosisIh Chang, Ludwig Kappos, Gavin Giovannoni, et al.
The New England Journal of Medicine|May 18, 2012
Risk of natalizumab-associated progressive multifocal leukoencephalopathyGary Bloomgren, Sandra Richman, Christophe Hotermans, et al.
Acta Neuropathologica|May 17, 2022
Alzheimer disease neuropathology in a patient previously treated with aducanumabEdward D Plowey, Thierry Bussiere, Raj Rajagovindan, et al.
Pageof 2